Vol. 54, No. 2
2020

The Bovine PRACTITIONER

THE OFFICIAL PUBLICATION OF THE
AMERICAN ASSOCIATION OF BOVINE PRACTITIONERS

ISSN 0524-1685

The Bovine PRACTITIONER

Vol. 54, No. 2
2020

EDITOR:
ROBERT A. SMITH, DVM
3404 Live Oak Lane
Stillwater, Oklahoma 74075
Tel: (405) 743-9133
Fax: (405) 743-8422
cowdr@sbcglobal.net

PUBLISHER:
VM PUBLISHING COMPANY
205 W. 7th Avenue, Suite 201
Stillwater, Oklahoma 74074
Tel/Fax: (405) 533-1883
kellijo.vmpubco@gmail.com

THE BOVINE PRACTITIONER is published by The American Association of Bovine Practitioners, at **VM Publishing Company, LLC, 205 W. 7th, Suite 201, Stillwater, OK 74074 (Telephone and Fax: (405) 533-1883)**. Copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to:

AABP
1130 East Main Street, Suite 302
Ashland, Ohio 44805
Tel: (419) 496-0685; FAX (419) 496-0697
e-mail: aabphq@aabp.org
http://www.aabp.org

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in the spring and summer annually. It serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English. Beginning in 2019, THE BOVINE PRACTITIONER is an open access journal.

Copies of THE BOVINE PRACTITIONER are available to non-members. **Contact editor for details and subscription prices.**

Table of Contents

Advertisers Index

Cover photo courtesy of Jennifer L. Nightingale, DVM, Countryside Veterinary Clinic, Lowville, NY.

Notice to Readers

All statements, opinions and conclusions contained in articles in *The Bovine Practitioner* are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.

Editorial Review Board 2020

The Bovine Practitioner **articles are reviewed by three Editorial Review Board members. Reviewers for 2020 included:**

Dr. David Anderson
Knoxville, TN

Dr. Kevin Anderson
Raleigh, NC

Dr. Chance Armstrong
Baton Rouge, LA

Dr. Ruth Blauwiekel
Colchester, VT

Dr. Robert Callan
Ft. Collins, CO

Dr. Vickie L. Cooper
Ames, IA

Dr. Robert Corbett
Spring City, UT

Dr. Brent Credille
Bishop, GA

Dr. Russ Daly
Brookings, SD

Dr. Lionel Dawson
Stillwater, OK

Dr. Andre Desrochers
St-Hyacinthe, Quebec, Canada

Dr. Renee Dewell
Ames, IA

Dr. Grant Dewell
Ames, IA

Dr. Tyler Dohlman
Ames, IA

Dr. Terry Engelken
Ames, IA

Dr. Charles Estill
Corvallis, OR

Dr. Derek Foster
Raleigh, NC

Dr. Franklyn Garry
Ft. Collins, CO

Dr. Philippa Gibbons
Speedwell, TN

Dr. John Gilliam
Stillwater, OK

Dr. Sandra Godden
St. Paul, MN

Dr. Pat Gorden
Ames, IA

Dr. Meggan Graves
Knoxville, TN

Dr. Dee Griffin
Canyon, TX

Dr. Brad Heins
Watkinsville, GA

Dr. Larry C. Hollis
Flint, TX

Dr. Richard Hopper
Auburn, AL

Dr. Andy Johnson
Green Bay, WI

Dr. Meredyth Jones
Perkins, OK

Dr. Erin King
Woodstock, CT

Dr. Jennifer Koziol
West Lafayette, IN

Dr. Brian Lubbers
Manhattan, KS

Dr. Kaitlyn Lutz
Geneva, NY

Dr. Matt Miesner
Manhattan, KS

Dr. Dale Moore
Moscow, ID

Dr. Pierre-Yves Mulon
Knoxville, TN

Dr. Christine Navarre
Baton Rouge, IA

Dr. Terri Ollivett
Madison, WI

Dr. Craig Payne
Columbia, MO

Dr. Dan Posey
Amarillo, TX

Dr. Jeremy G. Powell
Fayetteville, AR

Dr. D. Owen Rae
Gainesville, FL

Dr. Ryan Rademacher
Okotoks, Alberta, Canada

Dr. Emily Reppert
Manhattan, KS

Dr. John Richeson
Canyon, TX

Dr. Karen Rogers
Greeley, CO

Dr. Emmanuel Rollin
Athens, GA

Dr. Allen Roussel
College Station, TX

Dr. Loren Schultz
Columbia, MO

Dr. Jan Shearer
Ames, IA

Dr. Katie Simpson
Fort Collins, CO

Dr. David Smith
Mississippi State, MS

Dr. Lynn Steadman
Chadron, NE

Dr. Gerald Stokka
Cooperstown, ND

Dr. Bill Stone
Auburn, NY

Dr. Anthony Tarpoff
Manhattan, KS

Dr. Miles Theurer
Montezuma, KS

Dr. Dan Thomson
Ames, IA

Dr. Michael Van Amburgh
Ithaca, NY

Dr. Brian Vander Ley
Clay Center, NE

Dr. Kevin Washburn
College Station, TX

Dr. Lou Anne Wolfe
Claremore, OK

Appreciation is extended to each board member for volunteering their time and expertise to review articles for *The Bovine Practitioner*.

READY. SET. ZUPREVO®

(tildipirosin)

When you spot bovine respiratory disease (BRD), reach for the fast that lasts.

Reaching **peak plasma levels in 45 minutes**, ZUPREVO gets to work rapidly. Its unique chemical structure results in swift accumulation in the lungs and keeps working **for 28 days** in lung tissue.[1]

With ZUPREVO, you can give clients the therapy they need to win the race against BRD. Fast-acting, long-lasting solutions are another way Merck Animal Health Works for you and your clients.

See the full prescribing information at Zuprevo.com.



[1]Menge M, et al,. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, non-anesthetized cattle). *J Vet Pharmacol Ther.* 2012;35(6):550-559. The correlation between pharmacokinetic data and clinical relevance is unknown.

IMPORTANT SAFETY INFORMATION: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN. RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residue. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. The effects of Zuprevo® 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter. DO NOT USE ZUPREVO® 18% IN SWINE. FATAL ADVERSE EVENTS HAVE BEEN REPORTED FOLLOWING THE USE OF TILDIPIROSIN IN SWINE. NOT FOR USE IN CHICKENS OR TURKEYS.

MAHCattle.com • 800-521-5767

MERCK Animal Health

PRODUCT INFORMATION
NADA 141-334, Approved by FDA.

ZUPREVO® 18%
(tildipirosin)

Injectable Solution for Cattle

ANTIMICROBIAL DRUG
180 mg of tildipirosin/mL For subcutaneous injection in beef and non-lactating dairy cattle only.

Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

BRIEF SUMMARY: for full prescribing information use package insert.

INDICATIONS: Zuprevo® 18% is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida*, and *Histophilus somni* in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica*, *P. multocida,* and *H. somni.*

WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.

Avoid direct contact with skin and eyes. If accidental eye exposure occurs, rinse eyes with clean water. If accidental skin exposure occurs, wash the skin immediately with soap and water. Tildipirosin may cause sensitization by skin contact.

For technical assistance or to report a suspected adverse reaction, call: 1-800-219-9286.

For customer service or to request a Material Safety Data Sheet (MSDS), call: 1-800-211-3573. For additional Zuprevo 18% information go to www.zuprevo.com.

For a complete listing of adverse reactions for Zuprevo 18% reported to CVM see: http://www.fda.gov/AnimalVeterinary/SafetyHealth.

DO NOT USE ZUPREVO 18% IN SWINE.
Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

PRECAUTIONS: The effects of Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

Made in Germany
Distributed by: Intervet Inc d/b/a Merck Animal Health, Summit, NJ 07901

Moraxella bovoculi Bacterin

World's First Commercially Available Moraxella bovoculi Pinkeye Preventative!

- 8 Different M. bovoculi Isolates
- Cost Effective for All Cattle Herds
- Proven Safety Record
- More Convenient than Autogenous Programs



Addison Biological Laboratory, Inc. announces the approval of the world's first commercial Moraxella bovoculi vaccine for the prevention of pinkeye in cattle. This USDA conditionally licensed product is the first of this kind. Previously the only method of prevention against *Moraxella bovoculi* was autogenous services. This vaccine signifies a breakthrough in convenience for the large number of veterinarians and herd owners battling the challenging problem of pinkeye caused by *Moraxella bovoculi*. This product license is conditional; efficacy and potency have not been fully demonstrated.

From the LEADERS in pinkeye prevention!

ADDISON BIOLOGICAL LABORATORY

Addison Biological Laboratory, Inc.
www.addisonlabs.com
info@addisonlabs.com
800-331-2530